{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:27Z","timestamp":1793037627290,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009437","name":"Tel Aviv Sourasky Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009437","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2026.e00837","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T20:12:29Z","timestamp":1769285549000},"page":"e00837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies"],"prefix":"10.1016","volume":"23","author":[{"given":"Lior","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifat","family":"Vigiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian E.","family":"Drory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Dori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Magalashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Caller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Kenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Mechnik Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Wilf-Yarkoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Friedman Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Bsoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahar","family":"Shelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-7900","authenticated-orcid":false,"given":"Arnon","family":"Karni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e00837_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.neurot.2026.e00837_bib2","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00837_bib3","first-page":"727","article-title":"Update on myasthenia gravis: epidemiology, pathogenesis, and treatment","volume":"61","author":"Narayanaswami","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2026.e00837_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00837_bib5","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00837_bib7","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00837_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience","volume":"96","author":"Moniz Dion\u00edsio","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00837_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.28003","article-title":"Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events","volume":"69","author":"Singer","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2026.e00837_bib12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mus.27974","article-title":"Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"68","author":"Katyal","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2026.e00837_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1472845","article-title":"Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients","volume":"15","author":"Nomura","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib14","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib15","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2026.e00837_bib17","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-world experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/mus.28184","article-title":"Efgartigimod in refractory autoimmune myasthenia gravis","volume":"70","author":"Remijn-Nelissen","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2026.e00837_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114603","article-title":"Efficacy of multi-cycle efgartigimod in achieving minimal symptom expression in myasthenia gravis: a comparative multi-center study","volume":"154","author":"Chen","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.neurot.2026.e00837_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1555068","article-title":"Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors","volume":"16","author":"Sgarzi","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251319656","article-title":"Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes","volume":"18","author":"Jin","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00837_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","article-title":"New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making","volume":"39","author":"Gerischer","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.neurot.2026.e00837_bib24","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40265-024-02101-9","article-title":"Efgartigimod: a review in generalised myasthenia gravis","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2026.e00837_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00837_bib26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40120-025-00748-4","article-title":"Real-world experience with FcRn inhibitors efgartigimod and rozanolixizumab in myasthenia gravis: administration in multiple cycles and transition from intravenous to subcutaneous formulation","volume":"14","author":"Yoshikawa","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2026.e00837_bib27","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/acn3.70051","article-title":"ADAPT NXT: fixed cycles or every-other-week IV efgartigimod in generalized myasthenia gravis","volume":"12","author":"Habib","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib28","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00837_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123652","article-title":"Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis","volume":"477","author":"Goyal","year":"2025","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurot.2026.e00837_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103875","article-title":"Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells","volume":"24","author":"Man\u00e9-Damas","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.neurot.2026.e00837_bib31","doi-asserted-by":"crossref","DOI":"10.2174\/011570159X366227250716054651","article-title":"A prospective clinical trial of efgartigimod for new-onset generalized myasthenia gravis","author":"Ma","year":"2025","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.neurot.2026.e00837_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00837_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:05:57Z","timestamp":1772856357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747926000073"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00837","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00837"}}